Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease
Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed